Profile data is unavailable for this security.
About the company
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
- Revenue in USD (TTM)8.50m
- Net income in USD-31.19m
- Incorporated2015
- Employees13.00
- LocationApollomics Inc989 East Hillsdale Blvd, Ste 220FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 209-4055
- Websitehttps://www.apollomicsinc.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NanoViricides, Inc | 0.00 | -8.13m | 18.33m | 7.00 | -- | 2.08 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 18.36m | 2.00 | -- | 2.25 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.54m | 13.00 | -- | 0.5514 | -- | 35.38 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| IN8bio Inc | 0.00 | -20.66m | 18.56m | 18.00 | -- | 0.6611 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| LeonaBio Inc | 0.00 | -37.72m | 18.89m | 26.00 | -- | 0.7053 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 19.81m | 1.00 | -- | 0.663 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 19.95m | 59.00 | -- | 0.296 | -- | 27.10 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 20.35m | 5.00 | -- | 2.30 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 20.52m | 13.00 | -- | -- | -- | 2.41 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 21.01m | 66.00 | -- | -- | -- | 2.25 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 21.20m | 4.00 | -- | 367.73 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.48m | 7.00 | -- | 0.7529 | -- | 1.37 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 21.62m | 34.00 | -- | 2.66 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.91m | 18.00 | -- | 1.54 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.35m | 23.05m | 80.00 | -- | 24.50 | -- | -- | -1.34 | -1.34 | 0.00 | 0.0131 | 0.00 | -- | -- | 0.00 | -136.03 | -58.51 | -184.96 | -64.76 | -- | -- | -- | -- | -- | -- | 0.9482 | -- | -- | -- | -10.93 | -- | -- | -- |
| Evaxion A/S (ADR) | 7.65m | -5.42m | 23.06m | 46.00 | -- | -- | -- | 3.01 | -16.88 | -16.88 | 2.18 | -- | -- | -- | -- | 166,326.10 | -- | -96.54 | -- | -126.06 | -- | -- | -70.88 | -2,792.25 | -- | -- | -- | -- | 4,480.82 | -- | 52.24 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Dec 2025 | 64.00 | 0.01% |
| Harbour Investments, Inc.as of 30 Sep 2025 | 50.00 | 0.01% |
| SBI Securities Co., Ltd.as of 30 Sep 2025 | 19.00 | 0.00% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.00 | 0.00% |
